Ethics Committee approval for ValiRx's Georgia site "very important"
Dr Suzy Dilly, co-inventor of VAL401 and chief scientific officer at ValiRx Plc (LON:VAL), tells Proactive Investors the positive opinion received from the Ethics Committee recommending the trial protocol of its clinical site in Georgia is "very important."
It’s a significant milestone in ValiRx’s bid to take its flagship drug for non-small lung cancer into a phase ll clinical study. Dilly says the patients who will be recruited for the trial are those that have failed previous chemotherapies and further to the palliative benefits of VAL401, the quality of life indicators will also be "very important."
The chief scientific officer believes: “The treatment should be making people feel better and not just making them survive the side-effects of the drug."
#suzy, #dilly, #VAL401, #LON:VAL, #valiRx, #cancer, #lung, #study, #drug, #biotech, #tangent, #reprofiling, #georgia, #medical, #non-small